Biollistics
Bleeding and clot formation are key complications with the use of blood-contacting devices. Ension has developed a unique heparin-based coating that, while specifically optimized for mass exchange devices such as blood oxygenators, is applicable to all blood-biomaterial device surfaces. This coating demonstrates both significantly increased bioactivity and long-term stability while also remaining controllable and cost-effective to utilize on a mass production basis. Biollistics, Inc. is in the formation process as the vehicle to carry this coating technology to market.
